Short Interest in Autolus Therapeutics plc (NASDAQ:AUTL) Increases By 12.4%

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) was the target of a large growth in short interest in January. As of January 15th, there was short interest totalling 8,630,000 shares, a growth of 12.4% from the December 31st total of 7,680,000 shares. Based on an average daily trading volume, of 1,830,000 shares, the short-interest ratio is presently 4.7 days.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Redburn Atlantic raised shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 price target for the company in a report on Friday, November 15th. Needham & Company LLC reaffirmed a "buy" rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research note on Monday, January 13th. Finally, The Goldman Sachs Group upgraded shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and increased their target price for the stock from $7.00 to $7.60 in a report on Monday, November 18th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $10.40.

Autolus Therapeutics Trading Down 2.1 %

Autolus Therapeutics stock traded down $0.05 during midday trading on Wednesday, hitting $2.13. The stock had a trading volume of 1,026,964 shares, compared to its average volume of 1,101,716. The stock has a market cap of $565.44 million, a P/E ratio of -1.76 and a beta of 2.02. Autolus Therapeutics has a 12 month low of $2.07 and a 12 month high of $7.37. The business has a fifty day moving average price of $2.49 and a 200 day moving average price of $3.40.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period last year, the business posted ($0.26) earnings per share. On average, equities analysts anticipate that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

Institutional Trading of Autolus Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. HealthInvest Partners AB grew its position in shares of Autolus Therapeutics by 8.4% in the fourth quarter. HealthInvest Partners AB now owns 479,644 shares of the company's stock valued at $1,060,000 after purchasing an additional 37,221 shares during the last quarter. Handelsbanken Fonder AB raised its stake in shares of Autolus Therapeutics by 30.9% in the fourth quarter. Handelsbanken Fonder AB now owns 73,300 shares of the company's stock valued at $172,000 after acquiring an additional 17,300 shares during the last quarter. Aubrey Capital Management Ltd bought a new position in shares of Autolus Therapeutics in the fourth quarter valued at approximately $199,000. Dumont & Blake Investment Advisors LLC bought a new position in shares of Autolus Therapeutics in the fourth quarter valued at approximately $35,000. Finally, Arkadios Wealth Advisors bought a new position in shares of Autolus Therapeutics in the fourth quarter valued at approximately $47,000. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.